Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- People who have been diagnosed with lung cancer that has been confirmed through a tissue sample or cell sample test
- People who have previously received EGFR inhibitor treatment may still be eligible (confirm with trial site)
Who may not be able to join:
- No specific exclusion criteria were listed in the available information (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jonathan Riess, MD, University of California, Davis
Phone: 916-382-6970
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mutational status of the EGFR pathway
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.